title: 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension.
abstract: OBJECTIVE
  To evaluate the efficacy between Travoprost 0.004%/Timolol 0.5% fixed combination, Latanoprost 0.005%/ Timolol 0.5% fixed combination once a day in the morning and Timolol 0.5% twice a day in a 24-hour intraocular pressure control (IOP).
  
  
  METHODS
  The patients with primary open angle glaucoma and ocular hypertension was subjected. After 2-4 weeks of washout period, patients with daytime IOP > or = 21 mmHg and < 36 mmHg were admitted to the hospital for 24-hour IOP monitoring every 3-hour interval starting from 9 am to 9 am the next day. The patients were randomly received Travoprost-Timolol fixed combination, Latanoprost-Timolol fixed combination once a day or Timolol twice a day in the studied eyes. Another 24-hour IOP monitoring was taken again 2 weeks later.
  
  
  RESULTS
  59 eyes from 32 patients were subjected. The mean initial IOP at 9 am was 21.6 mmHg. The mean reduction of IOP ranging from 1.6 to 7.3 mmHg for Travoprost-Timolol group, 1.5 to 8.2 mmHg for Latanoprost-Timolol group and 2.2 to 5.6 mmHg for Timolol group. All three groups produced statistically significant reduction (p < 0.05) in mean IOP at all test times except; at 3 am for the Travoprost-Timolol group; at 3 am, 12 midnight-and 6 pm in the Latanoprost-Timolol group; and at 3 am and 9 pm in the Timolol group. The effects of IOP reduction of the combination drugs were greatest between 9 am and 3 pm with the morning dose of both combinations. There was no statistically significant difference in mean IOP reduction at any test time between the 2 combination drug groups but they were both better than Timolol alone at 9 am and 3 pm.
  
  
  CONCLUSIONS
  A fixed combination of Travoprost 0.004% and Timolol 0.5% is as effective as a fixed combination of Latanoprost 0.005% and Timolol 0.5% and are better than Timolol 0.5% in 24-hour IOP control.
authors: Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand. pongsakpachimkul@gmail.com
authors: Pongsak
authors: P
authors: Pachimkul
authors: Kanokwan
authors: K
authors: Yuttitham
authors: Peerapong
authors: P
authors: Thoophom
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004338:Drug Combinations; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage*; D000069557:Travoprost; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D013999:Timolol; D000069557:Travoprost